FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2955804906> ?p ?o ?g. }

• W2955804906 endingPage "S152" @default.
• W2955804906 startingPage "S152" @default.
• W2955804906 abstract "To investigate and compare baseline demographic and clinical characteristics of patients with type 2 diabetes (TD2) who are new users of sodium-glucose cotransporter-2 Inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs). This retrospective observational study utilized administrative claims from a regional health plan to assess demographic and clinical profiles of patients with T2D who are new users of SGLT-2is or GLP-1RAs. Patients were included if they met the following criteria: ≥18 years of age at index date, ≥1 medical claim with a T2D ICD-9/10 diagnosis, new users of SGLT-2is or GLP-1RAs between March 1, 2013 and November 30, 2018, and continuous enrollment ≥12 months pre-index (baseline). Index date was defined as the earliest fill for either drug class. New users were defined as having no prescription fills for either drug class at baseline. Patients were divided into SGLT-2i and GLP-1RA cohorts, based on index medication identified. Descriptive statistics and bivariate analyses were performed on all measures to detect differences between groups. Overall, 431(48.6%) patients were initiated on SGLT-2is and 456(51.4%) on GLP-1RAs. Mean age was approximately 56-57 years across both cohorts. There were significantly more females in the GLP-1RA group (58.1 versus 49.0%,p=0.006). A total of 98(11%) patients had clinical ASCVD with no significant difference between groups. GLP-1RA patients were more obese (35.8% versus 26.2%,p=0.0022) and had higher prevalence of peripheral neuropathy (43.9% versus 37.1%;p=0.0411), nephropathy (37.1% versus 29.0%;p=0.0108), and CKD (10.5% versus 3.5%,p<0.0001). Medication utilization was similar across both groups, except for higher ACE-inhibitor and sulfonylurea use in the GLP-1RA group (11.4% versus 5.8%,p=0.0031 and 13.6% versus 8.4%,p=0.0213, respectively). Differences in comorbidities were found between both groups, specifically for obesity, nephropathy, neuropathy, and CKD, while medication utilization was relatively similar. Future research comparing cardiovascular outcomes between SGLT-2is and GLP-1RAs is needed and should take into account these baseline characteristics." @default.
• W2955804906 created "2019-07-12" @default.
• W2955804906 creator A5012313192 @default.
• W2955804906 creator A5036392287 @default.
• W2955804906 creator A5037714580 @default.
• W2955804906 creator A5040213734 @default.
• W2955804906 creator A5083468863 @default.
• W2955804906 date "2019-05-01" @default.
• W2955804906 modified "2023-09-26" @default.
• W2955804906 title "PDB68 DEMOGRAPHIC AND CLINICAL PROFILES OF PATIENTS WITH TYPE 2 DIABETES NEWLY INITIATING SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS COMPARED TO GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS" @default.
• W2955804906 doi "https://doi.org/10.1016/j.jval.2019.04.617" @default.
• W2955804906 hasPublicationYear "2019" @default.
• W2955804906 type Work @default.
• W2955804906 sameAs 2955804906 @default.
• W2955804906 citedByCount "0" @default.
• W2955804906 crossrefType "journal-article" @default.
• W2955804906 hasAuthorship W2955804906A5012313192 @default.
• W2955804906 hasAuthorship W2955804906A5036392287 @default.
• W2955804906 hasAuthorship W2955804906A5037714580 @default.
• W2955804906 hasAuthorship W2955804906A5040213734 @default.
• W2955804906 hasAuthorship W2955804906A5083468863 @default.
• W2955804906 hasBestOaLocation W29558049061 @default.
• W2955804906 hasConcept C126322002 @default.
• W2955804906 hasConcept C134018914 @default.
• W2955804906 hasConcept C167135981 @default.
• W2955804906 hasConcept C170493617 @default.
• W2955804906 hasConcept C185280430 @default.
• W2955804906 hasConcept C2426938 @default.
• W2955804906 hasConcept C2777180221 @default.
• W2955804906 hasConcept C2778938600 @default.
• W2955804906 hasConcept C555293320 @default.
• W2955804906 hasConcept C71924100 @default.
• W2955804906 hasConcept C98274493 @default.
• W2955804906 hasConceptScore W2955804906C126322002 @default.
• W2955804906 hasConceptScore W2955804906C134018914 @default.
• W2955804906 hasConceptScore W2955804906C167135981 @default.
• W2955804906 hasConceptScore W2955804906C170493617 @default.
• W2955804906 hasConceptScore W2955804906C185280430 @default.
• W2955804906 hasConceptScore W2955804906C2426938 @default.
• W2955804906 hasConceptScore W2955804906C2777180221 @default.
• W2955804906 hasConceptScore W2955804906C2778938600 @default.
• W2955804906 hasConceptScore W2955804906C555293320 @default.
• W2955804906 hasConceptScore W2955804906C71924100 @default.
• W2955804906 hasConceptScore W2955804906C98274493 @default.
• W2955804906 hasLocation W29558049061 @default.
• W2955804906 hasOpenAccess W2955804906 @default.
• W2955804906 hasPrimaryLocation W29558049061 @default.
• W2955804906 hasRelatedWork W1563850031 @default.
• W2955804906 hasRelatedWork W2032287785 @default.
• W2955804906 hasRelatedWork W2094113608 @default.
• W2955804906 hasRelatedWork W2167444163 @default.
• W2955804906 hasRelatedWork W2233866314 @default.
• W2955804906 hasRelatedWork W2374391052 @default.
• W2955804906 hasRelatedWork W2383009242 @default.
• W2955804906 hasRelatedWork W2415759662 @default.
• W2955804906 hasRelatedWork W3036934084 @default.
• W2955804906 hasRelatedWork W88627568 @default.
• W2955804906 hasVolume "22" @default.
• W2955804906 isParatext "false" @default.
• W2955804906 isRetracted "false" @default.
• W2955804906 magId "2955804906" @default.
• W2955804906 workType "article" @default.